JAX_CKB's profile picture. JAX-CKB: #PrecisionMedicine platform by @jacksonlab for interpreting human #cancer variants, #genomics & #proteomics, to match to therapies and #clinicaltrials.

JAX Clinical Knowledgebase (JAX-CKB)

@JAX_CKB

JAX-CKB: #PrecisionMedicine platform by @jacksonlab for interpreting human #cancer variants, #genomics & #proteomics, to match to therapies and #clinicaltrials.

Pinned

CKB's New #cancer variant navigation is out! Learn more here: ckbhome.jax.org/about/category…


JAX Clinical Knowledgebase (JAX-CKB) reposted

📰 New on the JAX Blog: The task of finding variants that potentially contribute to drug resistance can be overwhelming. Read how the @JAX_CKB is an invaluable resource in identifying a list of potential resistance variants for preclinical testing: jax.org/news-and-insig…


Interesting study on how IL-17 can drive resistance to anti-PD-L1 treatment! #immunotherapy #cancerresearch #cytokines

Xing Chen et al. report that IL-17, a proinflammatory cytokine widely associated with poor prognosis in solid tumors, drives the therapeutic failure of anti–PD-L1. bit.ly/372UZ6f From our #Cancer #Immunotherapy collection: bit.ly/3UB7vxh #SITC22

JExpMed's tweet image. Xing Chen et al. report that IL-17, a proinflammatory cytokine widely associated with poor prognosis in solid tumors, drives the therapeutic failure of anti–PD-L1. bit.ly/372UZ6f

From our #Cancer #Immunotherapy collection: bit.ly/3UB7vxh

#SITC22


#AMPath22 attendees, looking for a resource to interpret genomic variants and find treatment options and clinical trials? Come visit us at booth #940 and ask for a CKB demo! #ClinicalKnowledgebase #PrecisionMedicine #PathTwitter 🧬

JAX_CKB's tweet image. #AMPath22 attendees, looking for a resource to interpret genomic variants and find treatment options and clinical trials? Come visit us at booth #940 and ask for a CKB demo! #ClinicalKnowledgebase #PrecisionMedicine #PathTwitter 🧬

Check out our latest blog post on how you can use CKB as a resource for preclinical drug testing! #AMPath22 attendees, visit us at booth 940 to learn more! resources.jax.org/jax-blog/jax-c… #cancerresearch #cancertreatments #PrecisionMedicine

JAX_CKB's tweet image. Check out our latest blog post on how you can use CKB as a resource for preclinical drug testing! #AMPath22 attendees, visit us at booth 940 to learn more! resources.jax.org/jax-blog/jax-c… #cancerresearch #cancertreatments #PrecisionMedicine

Attending #AMP2022 this week? Come visit our booth, #940, to learn more about how CKB can be used for interpreting genomic variants and finding relevant treatments and #clinicaltrials! #precisionmedicine #genomics #CancerResearch

JAX_CKB's tweet image. Attending #AMP2022 this week? Come visit our booth, #940, to learn more about how CKB can be used for interpreting genomic variants and finding relevant treatments and #clinicaltrials! #precisionmedicine #genomics #CancerResearch

JAX Clinical Knowledgebase (JAX-CKB) reposted

Early results from phase I ARROS-1 trial: NVL-520 in #ROS1 by Dr. @alexdrilon at #ENA2022. This novel ROS1 inhibitor is designed to avoid #NTRK (and TRK-related toxicities, which often limit dose intensity). Studied in a heavily pretreated population (71% with ≥2 TKIs and chemo)

StephenVLiu's tweet image. Early results from phase I ARROS-1 trial: NVL-520 in #ROS1 by Dr. @alexdrilon at #ENA2022. This novel ROS1 inhibitor is designed to avoid #NTRK (and TRK-related toxicities, which often limit dose intensity). Studied in a heavily pretreated population (71% with ≥2 TKIs and chemo)
StephenVLiu's tweet image. Early results from phase I ARROS-1 trial: NVL-520 in #ROS1 by Dr. @alexdrilon at #ENA2022. This novel ROS1 inhibitor is designed to avoid #NTRK (and TRK-related toxicities, which often limit dose intensity). Studied in a heavily pretreated population (71% with ≥2 TKIs and chemo)

Updates to CKB CORE and BOOST 👏! We've made some changes to improve search performance and enhance the search results for "Explore by Variant"! Check out this screenshot for--> #BRAFV600E in CKB CORE #CancerResearch #genomics #precisionmedicine

JAX_CKB's tweet image. Updates to CKB CORE and BOOST 👏! We've made some changes to improve search performance and enhance the search results for "Explore by Variant"! Check out this screenshot for--> #BRAFV600E in CKB CORE #CancerResearch #genomics #precisionmedicine

Are you attending #AMP2022? JAX-CKB will be there! Come visit us at booth #940 and learn how CKB can be used to interpret #cancer genomic profiles and identify treatment options! #precisionmedicine #cancerresearch #clinicaltrials

JAX_CKB's tweet image. Are you attending #AMP2022? JAX-CKB will be there! Come visit us at booth #940 and learn how CKB can be used to interpret #cancer genomic profiles and identify treatment options! #precisionmedicine #cancerresearch #clinicaltrials

CKB CORE users--> the next quarterly update to the gene list is now available! This quarter's theme is the tumor suppressor genes! ckb.jax.org #cancerresearch #genomics

JAX_CKB's tweet image. CKB CORE users--> the next quarterly update to the gene list is now available! This quarter's theme is the tumor suppressor genes! ckb.jax.org #cancerresearch #genomics

Check out this latest commentary on how to choose the best interpretation tools for your #oncology data! #precisionmedicine #genomics #CancerResearch bio-itworld.com/news/2022/10/1…

JAX_CKB's tweet image. Check out this latest commentary on how to choose the best interpretation tools for your #oncology data! #precisionmedicine #genomics #CancerResearch bio-itworld.com/news/2022/10/1…

JAX Clinical Knowledgebase (JAX-CKB) reposted

Check out our new publication: Remotely Guided Immunobots Engaged in Anti-Tumorigenic Phenotypes for Targeted Cancer Immunotherapy- where we convert live macrophages into robots for targeted immunoengineering. onlinelibrary.wiley.com/doi/full/10.10… @NihalOlcay @metin_sitti @MayoClinic @MPI_IS


JAX Clinical Knowledgebase (JAX-CKB) reposted

"Scientists are developing numerous approaches to make [cancer] immunotherapy safer, including drafting different immune cells, like the awesomely-named natural killer cells. Another option is Calibr’s off switch." freethink.com/health/switcha…


A great updated summary from @theNCI highlighting the advances in #BreastCancer research! #BreastCancerAwarenessMonth #CancerResearch

Our recently updated summary of advances in #BreastCancer research highlights clinical advances that may soon translate into improved care as well as findings from recent studies. Check it out! cancer.gov/types/breast/r… #BCSM

theNCI's tweet image. Our recently updated summary of advances in #BreastCancer research highlights clinical advances that may soon translate into improved care as well as findings from recent studies. Check it out! cancer.gov/types/breast/r… #BCSM


Interesting study highlighting a new potential mechanism for resistance to immunotherapy -->cancer cells hiding within one another- "transient cell-in-cell structures" #immunotherapy #precisiononcology #CancerResearch doi.org/10.7554/eLife.…


Did you know a large portion of the evidence in CKB is #preclinical? Learn more about the types of preclinical data available in CKB in our latest blog post! #CancerResearch #genomics #PrecisionMedicine jax.org/news-and-insig…

JAX_CKB's tweet image. Did you know a large portion of the evidence in CKB is #preclinical? Learn more about the types of preclinical data available in CKB in our latest blog post! #CancerResearch #genomics #PrecisionMedicine jax.org/news-and-insig…

Extensive review including the history of #immunotherapy, currently available treatment options, and future therapeutic targets across multiple #cancer types! @NaturePortfolio #PrecisionMedicine #immunoOncology pubmed.ncbi.nlm.nih.gov/36123348/

JAX_CKB's tweet image. Extensive review including the history of #immunotherapy, currently available treatment options, and future therapeutic targets across multiple #cancer types! @NaturePortfolio #PrecisionMedicine #immunoOncology  pubmed.ncbi.nlm.nih.gov/36123348/

JAX Clinical Knowledgebase (JAX-CKB) reposted

Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22 ✅Luminal A/B subtypes enriched in HER2Low vs HER2-0 ✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression ✅New diagnostic assays (mRNA?) needed @OncoAlert @myESMO

AMalfettonePhD's tweet image. Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22
✅Luminal A/B subtypes enriched in HER2Low vs HER2-0
✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression
✅New diagnostic assays (mRNA?) needed
@OncoAlert
@myESMO
AMalfettonePhD's tweet image. Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22
✅Luminal A/B subtypes enriched in HER2Low vs HER2-0
✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression
✅New diagnostic assays (mRNA?) needed
@OncoAlert
@myESMO
AMalfettonePhD's tweet image. Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22
✅Luminal A/B subtypes enriched in HER2Low vs HER2-0
✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression
✅New diagnostic assays (mRNA?) needed
@OncoAlert
@myESMO
AMalfettonePhD's tweet image. Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22
✅Luminal A/B subtypes enriched in HER2Low vs HER2-0
✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression
✅New diagnostic assays (mRNA?) needed
@OncoAlert
@myESMO

JAX Clinical Knowledgebase (JAX-CKB) reposted

Looking forward to chairing this study with @MeghnaTrivedi3 and working with my @jacksonlab colleagues in @JAXClinicalEd and @JAX_CKB

Do more #CancerPatients get genome-informed #cancer treatment when a genomic tumor board helps doctors choose treatments? Study S2108CD is designed to answer this question. Learn more at SWOG.org/S2108CD. Or call 1-800-4-CANCER. Ask about S2108CD. #bcsm #LCSM #CRCSM

SWOG's tweet image. Do more #CancerPatients get genome-informed #cancer treatment when a genomic tumor board helps doctors choose treatments? Study S2108CD is designed to answer this question. Learn more at SWOG.org/S2108CD. Or call 1-800-4-CANCER. Ask about S2108CD. #bcsm #LCSM #CRCSM


Exciting work going on for #KRAS #G12R-driven cancers! #cancerresearch #hotspotmutations

The to-do list is getting shorter. #G12R. The next #KRAS oncogene targeted by covalent chemistry. Great work @bignerdzzy @UCB_Chemistry @mo_hannes @ace_eckert @UCSF @HHMINEWS @UCSFCancer @acsJACS pubs.acs.org/doi/10.1021/ja…

kevansf's tweet image. The to-do list is getting shorter. #G12R.  The next #KRAS oncogene targeted by covalent chemistry.  Great work @bignerdzzy @UCB_Chemistry @mo_hannes @ace_eckert  @UCSF @HHMINEWS @UCSFCancer @acsJACS pubs.acs.org/doi/10.1021/ja…


Great overview of recent papers detailing the current treatment landscape and emerging #biomarkers in advanced hepatocellular carcinoma. @CCR_AACR #HCC #PrecisionMedicine #oncology pubmed.ncbi.nlm.nih.gov/35727695/

JAX_CKB's tweet image. Great overview of recent papers detailing the current treatment landscape and emerging #biomarkers in advanced hepatocellular carcinoma. @CCR_AACR #HCC #PrecisionMedicine #oncology 
pubmed.ncbi.nlm.nih.gov/35727695/

Loading...

Something went wrong.


Something went wrong.